Opthea returns to ASX and works to restart eye therapy candidate

Opthea, once one of Australia's most important emerging biotechnology companies, has announced it will redirect the development of OPT-302 to lymphangioleiomyomatosis, or LAM, a rare pulmonary disease with significant unmet need. …